Etrolizumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 457121719

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu/a

| target = β7 subunit of α4β7 and αEβ7 integrin heterodimers

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1044758-60-2

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = I2A72G2V3J

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| IUPHAR_ligand = 8407 | C=6396 | H=9874 | N=1702 | O=2010 | S=42

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09901

}}

Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7.Adis Insight [http://adisinsight.springer.com/drugs/800026082 Etrolizumab] {{Webarchive|url=https://web.archive.org/web/20160603093535/http://adisinsight.springer.com/drugs/800026082 |date=2016-06-03 }} Latest Information Update: 16 Dec 2015 Etrolizumab was developed by GenentechUK Medicines Information. [http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6112 etrolizumab at UKMI] {{Webarchive|url=https://web.archive.org/web/20160604005122/http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6112 |date=2016-06-04 }} Page accessed May 10, 2016{{Cite web|url=https://www.gene.com/medical-professionals/pipeline|title=Genentech: Our Pipeline|website=www.gene.com|access-date=2020-05-22|archive-date=2020-05-24|archive-url=https://web.archive.org/web/20200524223812/https://www.gene.com/medical-professionals/pipeline|url-status=live}} by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.{{cite patent | country = WO | number = 2012135589 | title = Methods of administering beta7 integrin antagonists | assign1 = Genentech and Roche}} For the FIB504 mAb, see Andrew DP et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. {{cite journal | vauthors = Andrew DP, Berlin C, Honda S, Yoshino T, Hamann A, Holzmann B, Kilshaw PJ, Butcher EC | title = Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation | journal = Journal of Immunology | volume = 153 | issue = 9 | pages = 3847–61 | date = November 1994 | doi = 10.4049/jimmunol.153.9.3847 | pmid = 7523506 | s2cid = 32434092 }} as referenced in paragraph 146 of the PCT application.

As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.{{cite journal | vauthors = Makker J, Hommes DW | title = Etrolizumab for ulcerative colitis: the new kid on the block? | journal = Expert Opinion on Biological Therapy | volume = 16 | issue = 4 | pages = 567–72 | date = 2016 | pmid = 26914639 | doi = 10.1517/14712598.2016.1158807 | s2cid = 24706213 }}{{cite journal | vauthors = Rosenfeld G, Parker CE, MacDonald JK, Bressler B | title = Etrolizumab for induction of remission in ulcerative colitis | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD011661 | date = December 2015 | volume = 2015 | pmid = 26630451 | doi = 10.1002/14651858.CD011661.pub2 | pmc = 8612697 }} According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events.{{cite journal | vauthors = Motaghi E, Ghasemi-Pirbaluti M, Zabihi M | title = Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison|url=https://www.researchgate.net/publication/328722610 | journal = Pharmacological Research | volume = 139 | pages = 120–125 | date = January 2019 | pmid = 30395950 | doi = 10.1016/j.phrs.2018.11.003 | s2cid = 53235342 }}

Phase III clinical trials produced mixed results; and, on October 14, 2020, Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease,{{cite journal |last1=Tong |first1=Amber |title=Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback |journal=Endpoints |date=October 15, 2020 |url=https://endpts.com/roche-writes-off-ulcerative-colitis-portion-of-etrolizumab-program-days-after-dissecting-phiii-setback |access-date=2 January 2021 |archive-date=24 November 2020 |archive-url=https://web.archive.org/web/20201124012928/https://endpts.com/roche-writes-off-ulcerative-colitis-portion-of-etrolizumab-program-days-after-dissecting-phiii-setback/ |url-status=live }} until disappointing trial results led to this being abandoned too in February 2022.{{cite web |url=https://www.fiercebiotech.com/biotech/roche-lets-go-etro-dumping-phase-3-crohn-s-prospect-18-months-after-posting-weak-colitis |website=Fierce Biotech |access-date=8 March 2023 |title=Archived copy |archive-date=8 March 2023 |archive-url=https://web.archive.org/web/20230308012715/https://www.fiercebiotech.com/biotech/roche-lets-go-etro-dumping-phase-3-crohn-s-prospect-18-months-after-posting-weak-colitis |url-status=live }}